Sarilumab

Sarilumab is a monoclonal antibody medication designed to treat inflammatory conditions such as rheumatoid arthritis. It works by blocking the action of interleukin-6 (IL-6), a protein in the body that contributes to inflammation.

Indications

Sarilumab is indicated for the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded well to other disease-modifying antirheumatic drugs (DMARDs).

Dosage

The recommended dosage of sarilumab is typically administered as a subcutaneous injection once every two weeks. The dosage may vary based on individual patient factors and response to treatment.

Contra-Indications

Sarilumab is contraindicated in patients with known hypersensitivity to sarilumab or any of its components.

Special Precautions

Patients receiving sarilumab should be monitored for signs of infection, including tuberculosis. Vaccinations should be administered prior to initiating treatment with sarilumab, as recommended by healthcare providers.

Side Effects

Common side effects of sarilumab may include upper respiratory tract infections, injection site reactions, and elevated liver enzymes. Serious side effects may include infections, gastrointestinal perforations, and hypersensitivity reactions.

Drug Interactions

Sarilumab may interact with other medications, including live vaccines and immunosuppressants. Patients should inform their healthcare providers of all medications they are taking before starting treatment with sarilumab.